reports
Marinus Pharmaceuticals Inc: 1 director sold
A director at Marinus Pharmaceuticals Inc sold 4,250 shares at 15.870USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epi...
RADNOR, Pa.--(BUSINESS WIRE)-- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has satisfied the FDA’s protocol-specific questions for the registrational Phase 3 trial (the RAISE trial) in refractory status epilepticus (RSE), allowing the company to begin enrollment in this clinical trial. In July, Marinus submitted a protocol amendment to the FDA for the RAISE trial for IV ganaxolone in RSE. Following a recent FDA discussion, Marinus currently anticipates the first patient will be enrolled i...
Marinus Announces One-for-Four Reverse Stock Split
RADNOR, Pa.--(BUSINESS WIRE)-- . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it will effect a one-for-four reverse stock split of its common stock at 5:00 pm ET today. Beginning with the opening of trading on September 23, 2020, the Company’s common stock will trade on The Nasdaq Global Market on a split-adjusted basis under a new CUSIP number 56854Q200. The Company’s stockholders approved an amendment authorizing the reverse stock split at its Special Meeting of Stockholders on March 31...
Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Defici...
RADNOR, Pa.--(BUSINESS WIRE)-- . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced positive top-line results from its registrational Phase 3 clinical trial () evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures. In the trial, patients given ganaxolone showed a significant 32.2 percent median reduction in 28-day major motor seizure frequency, compared to a 4.0 percent reduction for those receiving ...
Marinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment ...
RADNOR, Pa.--(BUSINESS WIRE)-- . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, to support the development of IV ganaxolone for the treatment of refractory status epilepticus (RSE), a life-threatening condition in which a significant number of pat...
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Heal...
RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at the Morgan Stanley Virtual Global Healthcare Conference, H.C Wainwright Virtual Global Investment Conference and Cantor Virtual Global Healthcare Conference during the week of September 14. Additional details can be found below: H.C. Wainwright Virtual Global Investment Conference Date: Tuesday, September 15 Time: 12:00 noon Eastern Time Presenter: Ed Smi...
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listi...
RADNOR, Pa.--(BUSINESS WIRE)-- (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of inducement awards to seven new employees. The independent members of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 453,500 shares of its common stock as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Of these stock option grants...
Marinus Pharmaceuticals Provides Business Update and Reports Second Qu...
RADNOR, Pa.--(BUSINESS WIRE)-- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical development activities and reported its financial results for the second quarter ended June 30, 2020. “We are very pleased to report that the company’s clinical programs continue to progress in line with the current timelines most recently discussed at our June 30 R&D Day, with limited disruptions attributable to COVID-19,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus. “We ...
Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation fr...
RADNOR, Pa.--(BUSINESS WIRE)-- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of , a rare refractory form of pediatric epilepsy. “We are pleased that ganaxolone has received Rare Pediatric Disease Designation from the FDA and are enthusiastic that the timing of this news aligns with our continued expectation to report top line da...
Marinus Pharmaceuticals Appoints Charles Austin to Board of Directors
RADNOR, Pa.--(BUSINESS WIRE)-- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Charles (“Chuck”) Austin to its Board of Directors. “Chuck is a recognized leader in the pharmaceutical and medical device industries,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus. “As a board member, we are excited to draw from his tremendous manufacturing and biopharma expertise as Marinus continues to grow and develop as an organization.” With more than 25 years of experien...
Marinus Pharmaceuticals Provides Pipeline Update
Marinus Pharmaceuticals Provides Pipeline Update Status Epilepticus pivotal Phase 3 trial on-track to begin in Q3 2020CDKL5 Deficiency Disorder Phase 3 trial results in Q3 2020 First patient enrolled in Phase 2 Tuberous Sclerosis Complex trial Enrollment in PCDH19 proof-of-concept trial increases to 25-30 patientsPipeline update webinar featuring four KOLs today at 8:00am ET RADNOR, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided a pipeline update in ...
Marinus Pharmaceuticals to Host Pipeline Update Webinar
Marinus Pharmaceuticals to Host Pipeline Update Webinar RADNOR, Pa., June 24, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a featuring a clinical update and commercial overview on its pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex. In addition, there will be four key opinion leaders participating in the event, which will take place on Preliminary Agenda: Marinus Overview Dr. Scott Braunstein, Chie...
Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2...
Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum RADNOR, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum. Additional details can be found below: Title: A Pipeline Update with Scott Braunstein (CEO) and Joe Hulihan (CMO)Date: Tuesday, June 23, 2020Time: 3:20 PM Eastern TimeFormat: Fireside chat About Marinus Pharmaceuticals Marinus P...
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listi...
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to a new employee. The Compensation Committee of the Board of Directors of Marinus granted Martha Manning, Esq., the Company’s new Vice President, General Counsel and Secretary, a non-qualified stock option to purchase an aggregate of 300,000 shares ...
Marinus Pharmaceuticals Appoints Martha Manning as Vice President, Gen...
Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and Secretary RADNOR, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced that Martha Manning, Esq., has been appointed Vice President, General Counsel and Secretary. “We are thrilled to welcome Martha to our growing team at Marinus, and believe her legal experience supporting biopharma companies across all development stages will be instrumental as we navigate through our...
Marinus Pharmaceuticals Announces Closing of $46 Million Public Offeri...
Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares RADNOR, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 18,400,000 shares of common stock at a public offering price of $2.50 per share, including the exercise in full by the underwriters of their option to purchase up to 2,400,000 additional shares of common stock. The offering raised gross pro...
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common...
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock RADNOR, Pa., May 28, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $2.50 per share. The gross proceeds of the offering to the Company are expected to be approximately $40,000,000, before deducting the underwriting di...
Marinus Pharmaceuticals Announces Proposed Public Offering of Common S...
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock RADNOR, Pa., May 28, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Marinus. The offering is subject to market conditions and there can be no assurance as to whether or when th...
Marinus Pharmaceuticals Provides Business Update and Reports First Qua...
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results Constructive End of Phase 2 Meeting with FDA for Status Epilepticus Completed in March; Pivotal Phase 3 Clinical Trial Expected to Begin Next Quarter Topline Data on Track for Q3 2020 from Pivotal Phase 3 Marigold Study in CDKL5 Deficiency Disorder and Preparations Continue for Potential NDA Filing First Patients to be Screened this Quarter for Phase 2 Tuberous Sclerosis Complex Clinical Trial RADNOR, Pa., May 04, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: MRNS), a pharmaceutical company dedicate...
Marinus Pharmaceuticals Announces Formation of Scientific Advisory Boa...
Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board Board includes 6 globally recognized seizure disorder experts RADNOR, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the formation of a Scientific Advisory Board (SAB) with the appointment of six leading experts in clinical neurology and seizure disorders: Jacqueline French, M.D., Lawrence Hirsch, M.D., Aatif Husain, M.D., Michael Rogawski M.D., Ph.D., Eugen Trinka, M.D. and He...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.